美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

美國抗疫概念

1,480.06

+12.920.88%

漲家數：10

跌家數：10

平家數：- -

市盈率：- -

高：1,487.39

開：1,467.14

低：1,462.61

收：1,467.14

資料載入中...

Equillium, Inc.盤中異動快速跳水6.19%

Corvus Pharmaceuticals, Inc.盤中異動股價大跌5.13%

Nanoviricides, Inc.盤中異動早盤大幅下挫5.04%報1.35美元

Ibio, Inc.盤中異動股價大漲5.23%

Co-Diagnostics, Inc.盤中異動股價大漲7.24%報0.655美元

一次宇宙級合作

困境Biotech這就不收購了？

輝瑞任命前FDA藥物主管為新任首席醫療官兼執行副總裁

吉利德(GILD.US)突破性長效HIV療法在歐洲獲得加速審評

輝瑞(PFE.US)達成臨牀開發合作評估雙抗新藥聯合治療多種實體瘤效果

港股異動 | 康方生物(09926)漲超5% 依沃西將與輝瑞多個ADCs藥物開展聯合療法臨牀試驗

前 FDA 藥品中心主任加入輝瑞，擔任首席醫療官

Insight数据库

【美國FDA前官員Cavazzoni將重返輝瑞，出任首席醫療官】輝瑞當地時間2月24日宣佈，Patrizia Cavazzoni將出任公司首席醫療官，接替將離職尋求其他機會的Aida Habtezion。Cavazzoni最近的職務是美國食品藥品監督管理局（FDA）藥物評估與研究中心主任，於今年1月辭職。在此之前，Cavazzoni曾在輝瑞擔任過多個高級職位，負責臨牀科學與開發業務。

GLP-1研發風雲錄：MetaBio折戟沉沙，輝瑞緣何錯失良機？

美股抗疫概念股漲跌不一，諾瓦瓦克斯醫藥跌逾7%

每日经济新闻

BUZZ-Summit Therapeutics 因第四季度虧損擴大和投資者對交易的預期而下跌

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK4568/news?page=8"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4568"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","market":"US","secType":"PLATE","nameCN":"美國抗疫概念","latestPrice":1480.0557,"timestamp":1741381199999,"preClose":1467.1393,"halted":0,"volume":126573383,"delay":0,"changeRate":0.008804,"change":12.916382,"pbRate":4.037358,"amount":7265241469.443725,"amplitude":0.016884,"prevYearClose":1274.8187,"fiveDayClose":1463.5875,"twentyDayClose":1359.8558,"turnoverRate":0.008184,"marketCap":1220494102080,"floatMarketCap":1198623322288,"peRate":31.999995},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","high":1487.3851,"amplitude":0.016884,"preClose":1467.1393,"low":1462.6143,"pbRate":"4.037358","latestPrice":1480.0557,"volume":126573383,"delay":0,"open":1467.1393,"prevYearClose":1274.8187,"prevWeekClose":1463.5875,"prevMonthClose":1463.5875,"prevQuarterClose":1274.8187,"fiveDayClose":1463.5875,"twentyDayClose":1359.8558,"sixtyDayClose":1300.6962,"secType":"PLATE","market":"US","turnoverRate":0.008184,"peRate":31.999995,"marketCap":1220494102080,"floatMarketCap":1198623322288,"timestamp":1741381199999,"nameCN":"美國抗疫概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4568\",,,,undefined,":{"bkCode":"BK4568","up":10,"down":10,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4568\",pageSize:16,pageCount:8,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514001149","title":"Equillium, Inc.盤中異動 快速跳水6.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514001149","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514001149?lang=zh_tw&edition=fundamental","pubTime":"2025-02-26 00:21","pubTimestamp":1740500464,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日00时21分，Equillium, Inc.股票出现波动，股价快速下跌6.19%。Equillium, Inc.股票所在的生物技术行业中，整体涨幅为0.56%。其相关个股中，Organovo Holdings, Inc.、Abpro Holdings Inc C/Wts 12/11/2029 、Silexion Therapeutics Corp涨幅较大，Organovo Holdings, Inc.、Gt Biopharma, Inc.、Silexion Therapeutics Corp较为活跃，换手率分别为1323.39%、1114.16%、898.01%，振幅较大的相关个股有Organovo Holdings, Inc.、Silexion Therapeutics Corp、Abpro Holdings Inc C/Wts 12/11/2029 ，振幅分别为224.93%、87.83%、66.67%。Equillium, Inc.公司简介：Equillium Inc 是一家开发治疗自身免疫和炎症疾病的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226002105a2539ffe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226002105a2539ffe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["EQ","BK4139","BK4568"],"gpt_icon":0},{"id":"2514013012","title":"Corvus Pharmaceuticals, Inc.盤中異動 股價大跌5.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514013012","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514013012?lang=zh_tw&edition=fundamental","pubTime":"2025-02-25 23:18","pubTimestamp":1740496685,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日23时18分，Corvus Pharmaceuticals, Inc.股票出现波动，股价大幅下跌5.13%。Corvus Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.89%。其相关个股中，Organovo Holdings, Inc.、Abpro Holdings Inc C/Wts 12/11/2029 、Lava Therapeutics N.V.涨幅较大，Gt Biopharma, Inc.、Organovo Holdings, Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为1050.65%、845.70%、586.00%，振幅较大的相关个股有Organovo Holdings, Inc.、Adial Pharmaceuticals, Inc、Silexion Therapeutics Corp，振幅分别为121.95%、63.66%、61.16%。Corvus Pharmaceuticals, Inc.公司简介：Corvus Pharmaceuticals Inc 是一家临床阶段的生物制药公司，致力于开发针对免疫系统关键细胞元素的药物和抗体。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225231805abdc89ff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225231805abdc89ff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4568","CRVS"],"gpt_icon":0},{"id":"2514001596","title":"Nanoviricides, Inc.盤中異動 早盤大幅下挫5.04%報1.35美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514001596","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514001596?lang=zh_tw&edition=fundamental","pubTime":"2025-02-25 23:08","pubTimestamp":1740496101,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日23时08分，Nanoviricides, Inc.股票出现异动，股价大幅下跌5.04%。截至发稿，该股报1.35美元/股，成交量6.6958万股，换手率0.43%，振幅8.35%。Nanoviricides, Inc.股票所在的生物技术行业中，整体涨幅为0.84%。Nanoviricides, Inc.公司简介：Nanoviricides Inc是一家纳米生物制药公司，致力于发现、开发和商业化治疗剂，以推进对患有危及生命的病毒感染患者的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225230821a253901b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225230821a253901b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NNVC","BK4568","BK4139"],"gpt_icon":0},{"id":"2514900770","title":"Ibio, Inc.盤中異動 股價大漲5.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514900770","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514900770?lang=zh_tw&edition=fundamental","pubTime":"2025-02-25 22:44","pubTimestamp":1740494666,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日22时44分，Ibio, Inc.股票出现异动，股价快速拉升5.23%。Ibio, Inc.股票所在的生物技术行业中，整体涨幅为0.37%。其相关个股中，Organovo Holdings, Inc.、Adial Pharmaceuticals, Inc、Abpro Holdings Inc C/Wts 12/11/2029 涨幅较大，Gt Biopharma, Inc.、Organovo Holdings, Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为855.06%、620.78%、532.76%，振幅较大的相关个股有Organovo Holdings, Inc.、Adial Pharmaceuticals, Inc、Gt Biopharma, Inc.，振幅分别为100.27%、46.65%、33.50%。Ibio, Inc.公司简介：iBio公司是一家临床前阶段生物技术公司，利用人工智能的力量开发精准抗体。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225224426962ff597&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225224426962ff597&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IBIO","BK4568","BK4139"],"gpt_icon":0},{"id":"2514090027","title":"Co-Diagnostics, Inc.盤中異動 股價大漲7.24%報0.655美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514090027","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514090027?lang=zh_tw&edition=fundamental","pubTime":"2025-02-25 22:32","pubTimestamp":1740493927,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日22时32分，Co-Diagnostics, Inc.股票出现波动，股价急速拉升7.24%。截至发稿，该股报0.655美元/股，成交量7873股，换手率0.02%，振幅0.02%。Co-Diagnostics, Inc.股票所在的医疗器械行业中，整体涨幅为0.06%。其相关个股中，Adapthealth Corp.、Pavmed Inc C/Wts 30/04/2025 Class Z、Nexalin Technology Inc C/Wts 涨幅较大，Reshape Lifesciences, Inc.、Nano-X Imaging Ltd、Sintx Technologies, Inc.较为活跃，换手率分别为26.37%、1.49%、1.14%，振幅较大的相关个股有Inspira Tech Oxy Bhn Ltd C/Wts 16/07/2026 、Pavmed Inc C/Wts 30/04/2025 Class Z、Axogen, Inc.，振幅分别为35.98%、14.29%、12.33%。Co-Diagnostics, Inc.公司简介：Co-Diagnostics Inc是一家分子诊断公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225223207abdc7e0a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225223207abdc7e0a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4568","BK4082","CODX"],"gpt_icon":0},{"id":"2514072060","title":"一次宇宙級合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2514072060","media":"瞪羚社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514072060?lang=zh_tw&edition=fundamental","pubTime":"2025-02-25 20:05","pubTimestamp":1740485100,"startTime":"0","endTime":"0","summary":"01辉瑞目前的困境众所周知，宇宙药厂辉瑞在新冠期间靠疫苗和特效药发了横财，并且在2024年，它都是制药业务板块营收最高的MNC。排名第一的是派柏西利，治疗乳腺癌的CDK4/6抑制剂，小分子爆款单品的代表，排名第二的是恩杂鲁胺，治疗前列腺癌的抗雄激素受体小分子。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226124834abdd4ad3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226124834abdd4ad3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2361044949.HKD","LU0320765489.SGD","LU0203347892.USD","LU2089984988.USD","SG9999014575.USD","SG9999001176.USD","LU0006306889.USD","LU1066053197.SGD","SMMT","SG9999013999.USD","LU2361045086.USD","LU1291159041.SGD","SGXZ57979304.SGD","IE00BJT1NW94.SGD","LU0208291251.USD","LU0070302665.USD","LU0238689110.USD","LU0456855351.SGD","IE00BFTCPJ56.SGD","LU1934455277.USD","LU1989772840.SGD","BK4568","LU1093756325.SGD","LU2468319806.SGD","LU1585245621.USD","PFE","LU0058720904.USD","SG9999001176.SGD","LU1037948897.HKD","LU2106854487.HKD","LU0225284248.USD","LU1934455863.HKD","SG9999002224.SGD","LU1162221912.USD","BK4588","IE00BSNM7G36.USD","LU1983299246.USD","BK4592","LU0170899867.USD","LU1894683264.USD","LU2023250843.SGD","LU1116320901.HKD","IE00BJJMRZ35.SGD","MRK","LU0211331839.USD","LU0266013472.USD","LU1023059063.AUD","BK4599","BK4139","BK4550"],"gpt_icon":0},{"id":"2514698690","title":"困境Biotech這就不收購了？","url":"https://stock-news.laohu8.com/highlight/detail?id=2514698690","media":"谈思生物","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514698690?lang=zh_tw&edition=fundamental","pubTime":"2025-02-25 15:21","pubTimestamp":1740468100,"startTime":"0","endTime":"0","summary":"2025.02.25本文字数：995，阅读时长大约3分钟导读：HOOKIPA Pharma因研发管线受挫、罗氏终止合作及投资机构信心不足，曾计划收购Poolbeg Pharma以拓展业务，但近期因资金状况改善而终止收购。然而，鉴于CAR-T市场增长放缓及Poolbeg核心产品POLB 001市场前景存疑，收购的必要性受到质疑。然而，最近HOOKIPA Pharma宣布终止收购计划。在这种背景下，即便HOOKIPA Pharma完成了对Poolbeg Pharma的收购，吉利德也未必会将Poolbeg的POLB 001纳入其开发计划。从这个角度来说，收购Poolbeg Pharma可能并不是一个明智的选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225175634abdc338d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225175634abdc338d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4578","IE00B7SZLL34.SGD","LU2089984988.USD","CAR","BK4566","LU1066053197.SGD","IE00B19Z3581.USD","IE00BZ1G4Q59.USD","LU1839511570.USD","LU0289739699.SGD","GILD","LU0234570918.USD","LU2087621335.USD","BK4230","BK4585","IE00BKVL7J92.USD","BK4583","BK4568","LU2468319806.SGD","LU1585245621.USD","LU0058720904.USD","LU1066051498.USD","LU0109394709.USD","BK4022","LU0320765992.SGD","BK4588","IE00BSNM7G36.USD","BK4532","LU1571399168.USD","IE0002270589.USD","IE00B19Z3B42.SGD","IE00B3T34201.USD","LU0889565916.HKD","BK4139","BK4550","LU1430594728.SGD"],"gpt_icon":0},{"id":"2514055452","title":"輝瑞任命前FDA藥物主管為新任首席醫療官兼執行副總裁","url":"https://stock-news.laohu8.com/highlight/detail?id=2514055452","media":"医药魔方","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514055452?lang=zh_tw&edition=fundamental","pubTime":"2025-02-25 15:11","pubTimestamp":1740467475,"startTime":"0","endTime":"0","summary":"2月24日，辉瑞宣布，前FDA药物主管Patrizia Cavazzoni将重新加入辉瑞，担任首席医疗官兼执行副总裁，领导辉瑞的监管、药物警戒、安全、流行病学、医疗信息和证据生成等医疗职能，并向辉瑞研发首席科学官兼总裁Chris Boshoff博士汇报。2019年，Cavazzoni加入FDA，担任代理首席副主任专员，并于2021年被任命为CDER的正式主任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225151629abdbf956&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225151629abdbf956&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0868494617.USD","BK4599","SGXZ57979304.SGD","LU1066051498.USD","IE00B19Z3581.USD","IE00B19Z3B42.SGD","LU1894683264.USD","LU0234572021.USD","LU1883839398.USD","BK4550","BK4534","LU0456855351.SGD","BK4533","SG9999011175.SGD","BK4588","SG9999001176.SGD","LU0306807586.USD","LU1066053197.SGD","LU1057294990.SGD","LU0321505868.SGD","SG9999013999.USD","IE00BBT3K403.USD","LU0321505439.SGD","SG9999002224.SGD","LU1023059063.AUD","PFE","BK4585","LU0170899867.USD","LU0225284248.USD","IE000M9KFDE8.USD","SG9999002232.USD","LU0058720904.USD","IE00BLSP4452.SGD","LU0985481810.HKD","SG9999001176.USD","BK4007","BK4592","IE0002270589.USD","LU0122379950.USD","SG9999003800.SGD","BK4568","LU0225771236.USD","LU0289739699.SGD","LU1894683348.USD","BK4581","LU0306806265.USD","IE00BLSP4239.USD"],"gpt_icon":1},{"id":"2514304620","title":"吉利德(GILD.US)突破性長效HIV療法在歐洲獲得加速審評","url":"https://stock-news.laohu8.com/highlight/detail?id=2514304620","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514304620?lang=zh_tw&edition=fundamental","pubTime":"2025-02-25 14:30","pubTimestamp":1740465038,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，吉利德科学公司今日宣布，欧洲药品管理局接受该公司为lenacapavir递交的上市许可申请，每半年注射一次，作为HIV感染的暴露前预防疗法。EMA人用药品委员会认为，每半年一次用于预防HIV感染的lenacapavir在公共卫生和治疗创新方面具有重大意义，上市申请将按加速审评时间表进行评估。在PURPOSE 2中，lenacapavir治疗组中99.9%的受试者未感染HIV，与背景HIV感染率相比，感染风险降低96%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1253915.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1839511570.USD","BK4566","LU2087621335.USD","BK4588","LU1571399168.USD","IE00B19Z3B42.SGD","BK4139","BK4550","GILD","LU2468319806.SGD","LU0058720904.USD","IE0002270589.USD","LU0320765992.SGD","LU1430594728.SGD","LU0109394709.USD","BK4532","LU1066051498.USD","LU1585245621.USD","IE00B19Z3581.USD","LU0889565916.HKD","BK4585","BK4568","LU0234570918.USD","BK4583","IE00BKVL7J92.USD","LU1066053197.SGD","LU0289739699.SGD","IE00BSNM7G36.USD","LU2089984988.USD","IE00B3T34201.USD","IE00BZ1G4Q59.USD","BK4578","IE00B7SZLL34.SGD"],"gpt_icon":0},{"id":"2514030461","title":"輝瑞(PFE.US)達成臨牀開發合作 評估雙抗新藥聯合治療多種實體瘤效果","url":"https://stock-news.laohu8.com/highlight/detail?id=2514030461","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514030461?lang=zh_tw&edition=fundamental","pubTime":"2025-02-25 14:29","pubTimestamp":1740464999,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，Summit Therapeutics公司今天宣布，与辉瑞开展临床试验合作，评估在研靶向PD-1/VEGF的双特异性抗体ivonescimab，与辉瑞的多种抗体偶联药物联用，治疗多种实体瘤的效果。康方生物公开资料指出，鉴于VEGF和PD-1在肿瘤微环境中的共表达，与联合疗法相比，该产品作为单一药物同时阻断这两个靶点，可能会更有效地阻断这两个信号通路，增强抗肿瘤活性。此外，与联合疗法相比，ivonescimab安全性优势显著，与VEGF靶点相关的毒副作用大幅度降低。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1253912.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SG9999002224.SGD","BK4581","LU0456855351.SGD","LU0868494617.USD","LU0234572021.USD","LU1057294990.SGD","LU0321505439.SGD","SG9999011175.SGD","BK4585","LU0985481810.HKD","SG9999001176.USD","BK4534","LU0225284248.USD","LU1883839398.USD","BK4007","SGXZ57979304.SGD","BK4588","BK4592","LU1894683264.USD","IE000M9KFDE8.USD","LU0225771236.USD","IE00BLSP4239.USD","BK4568","LU1066051498.USD","IE00BBT3K403.USD","PFE","SG9999013999.USD","LU0321505868.SGD","LU1066053197.SGD","LU1894683348.USD","IE00B19Z3581.USD","LU1023059063.AUD","LU0289739699.SGD","IE00BLSP4452.SGD","SG9999001176.SGD","SG9999003800.SGD","BK4599","BK4533","IE0002270589.USD","LU0058720904.USD","BK4550","IE00B19Z3B42.SGD","SG9999002232.USD","LU0122379950.USD","LU0170899867.USD","LU0306806265.USD","LU0306807586.USD"],"gpt_icon":1},{"id":"2514034005","title":"港股異動 | 康方生物(09926)漲超5% 依沃西將與輝瑞多個ADCs藥物開展聯合療法臨牀試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2514034005","media":"智通财经","labels":["corporation","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514034005?lang=zh_tw&edition=fundamental","pubTime":"2025-02-25 13:41","pubTimestamp":1740462061,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康方生物涨超5%，截至发稿，涨4.81%，报71.95港元，成交额9.44亿港元。消息面上，2月24日，康方生物宣布，依沃西国际市场开发合作伙伴Summit Therapeutics已与辉瑞达成临床试验合作，共同推进康方生物自主研发的PD-1/VEGF双抗依沃西与辉瑞多款抗体偶联药物在多种实体瘤中的联合治疗应用。公司指，此次合作的目标是深入挖掘依沃西联合辉瑞多款vedotin系列ADCs药物联合疗法在多种实体瘤中的协调潜力，加速推进可能重塑治疗格局的创新联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1253884.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","BK4585","LU0348784397.USD","SG9999001176.USD","BK1576","PFE","LU1894683348.USD","IE00BLSP4239.USD","IE00B19Z3B42.SGD","BK1574","LU0225771236.USD","LU0289739699.SGD","IE00BBT3K403.USD","LU0348783233.USD","SG9999011175.SGD","LU0122379950.USD","IE00B543WZ88.USD","LU0234572021.USD","LU0985481810.HKD","SGXZ57979304.SGD","BK4581","SG9999003800.SGD","03347","IE00B19Z3581.USD","BK4568","LU0456855351.SGD","BK4550","LU2488822045.USD","BK1141","IE000M9KFDE8.USD","BK4588","LU0058720904.USD","LU1794554557.SGD","LU0225284248.USD","IE00BPRC5H50.USD","LU0321505439.SGD","LU1023059063.AUD","LU0170899867.USD","LU1894683264.USD","LU1720050803.USD","LU0306806265.USD","SG9999002232.USD","LU1066051498.USD","09926","LU0868494617.USD","BK4592","IE00BLSP4452.SGD","SG9999001176.SGD","SG9999002224.SGD","SG9999013999.USD"],"gpt_icon":0},{"id":"2514051917","title":"前 FDA 藥品中心主任加入輝瑞，擔任首席醫療官","url":"https://stock-news.laohu8.com/highlight/detail?id=2514051917","media":"Insight数据库","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514051917?lang=zh_tw&edition=fundamental","pubTime":"2025-02-25 11:08","pubTimestamp":1740452908,"startTime":"0","endTime":"0","summary":"当地时间 2 月 24 日，根据外媒 Endpoint News 新闻，美国 FDA 前药品审评与研究中心主任 Patrizia Cavazzoni 将成为辉瑞新任首席医疗官，负责“监管、药物警戒、安全、流行病学以及医疗信息和证据生成”，直接向首席科学官 Chris Boshoff 汇报。加入 FDA 之前，Patrizia Cavazzoni 曾在制药行业工作多年。值得注意的是，前 FDA 局长 Scott Gottlieb 目前是辉瑞董事会成员。本月，FDA 设备和放射健康中心、烟草产品中心  和 CDER 多个部门又发生大规模裁员。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225155631abdc092f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225155631abdc092f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BBT3K403.USD","SG9999011175.SGD","BK4534","LU0225771236.USD","LU0289739699.SGD","PFE","BK4592","LU0306807586.USD","LU0306806265.USD","BK4599","LU0456855351.SGD","LU1066053197.SGD","BK4007","LU0234572021.USD","SG9999001176.USD","BK4588","SG9999002232.USD","LU1883839398.USD","SG9999001176.SGD","LU0170899867.USD","LU1894683348.USD","LU0122379950.USD","SG9999003800.SGD","LU0321505439.SGD","LU1057294990.SGD","IE00B19Z3B42.SGD","BK4550","BK4585","BK4568","IE00BLSP4239.USD","IE00B19Z3581.USD","LU0321505868.SGD","SG9999002224.SGD","LU0058720904.USD","IE00BLSP4452.SGD","LU0868494617.USD","SGXZ57979304.SGD","LU1023059063.AUD","LU1066051498.USD","LU0985481810.HKD","SG9999013999.USD","LU0225284248.USD","LU1894683264.USD","BK4533","BK4581","IE000M9KFDE8.USD","IE0002270589.USD"],"gpt_icon":1},{"id":"2514088626","title":"【美國FDA前官員Cavazzoni將重返輝瑞，出任首席醫療官】輝瑞當地時間2月24日宣佈，Patrizia Cavazzoni將出任公司首席醫療官，接替將離職尋求其他機會的Aida Habtezion。Cavazzoni最近的職務是美國食品藥品監督管理局（FDA）藥物評估與研究中心主任，於今年1月辭職。在此之前，Cavazzoni曾在輝瑞擔任過多個高級職位，負責臨牀科學與開發業務。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514088626","media":"金融界","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514088626?lang=zh_tw&edition=fundamental","pubTime":"2025-02-25 07:47","pubTimestamp":1740440856,"startTime":"0","endTime":"0","summary":"辉瑞当地时间2月24日宣布，Patrizia Cavazzoni将出任公司首席医疗官，接替将离职寻求其他机会的Aida Habtezion。Cavazzoni最近的职务是美国食品药品监督管理局（FDA）药物评估与研究中心主任，于今年1月辞职。在此之前，Cavazzoni曾在辉瑞担任过多个高级职位，负责临床科学与开发业务。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/25074748359132.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["IE00B19Z3581.USD","IE00BLSP4239.USD","SG9999002224.SGD","LU0170899867.USD","BK4588","159891","LU1894683264.USD","LU1023059063.AUD","SG9999011175.SGD","LU1883839398.USD","BK4533","LU0456855351.SGD","LU0225284248.USD","LU0234572021.USD","LU1066053197.SGD","IE00BLSP4452.SGD","LU0321505439.SGD","SG9999001176.SGD","BK4592","IE0002270589.USD","LU1066051498.USD","LU1894683348.USD","SG9999002232.USD","SG9999003800.SGD","BK4007","BK4585","LU1057294990.SGD","LU0225771236.USD","LU0321505868.SGD","PFE","BK4599","BK4534","SG9999013999.USD","BK4568","IE00B19Z3B42.SGD","LU0868494617.USD","LU0058720904.USD","IE00BBT3K403.USD","LU0985481810.HKD","BK4550","LU0306807586.USD","SGXZ57979304.SGD","LU0289739699.SGD","LU0306806265.USD","LU0122379950.USD","SG9999001176.USD","IE000M9KFDE8.USD","BK4581"],"gpt_icon":0},{"id":"2514088406","title":"GLP-1研發風雲錄：MetaBio折戟沉沙，輝瑞緣何錯失良機？","url":"https://stock-news.laohu8.com/highlight/detail?id=2514088406","media":"药渡","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514088406?lang=zh_tw&edition=fundamental","pubTime":"2025-02-25 07:30","pubTimestamp":1740439838,"startTime":"0","endTime":"0","summary":"一个月后，MetaBio获得了GLP-1用于糖尿病疗法的全球独家许可。正式合作法律文件于1988年7月签署，MetaBio/辉瑞合作研发正式启动。2辉瑞退出GLP-1合作开发MetaBio/辉瑞联盟由一个联合研究委员会监督，辉瑞任命全球研发高级副总裁和中央研究院研发运营总监负责该项目，辉瑞参与者的资历表明了他们兴趣的强烈程度。辉瑞表示，将确定开发除注射以外的GLP-1给药途径，例如经鼻或经皮。当时MetaBio团队和创始人强烈反对辉瑞的观点。之后诺和诺德获得了哈贝纳的GLP-1专利权。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225074833a25287d6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225074833a25287d6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","PFE","LU1057294990.SGD","IE000M9KFDE8.USD","LU0321505439.SGD","LU1023059063.AUD","SGXZ57979304.SGD","BK4144","BK4585","BK4533","BK4590","LU0170899867.USD","LU0868494617.USD","LU0122379950.USD","IE0002270589.USD","LU0306806265.USD","IE00B19Z3B42.SGD","SG9999013999.USD","BK4581","LU0225771236.USD","LU1066053197.SGD","LU0058720904.USD","SG9999002232.USD","LU1894683264.USD","LU0289739699.SGD","BK4568","LU0985481810.HKD","SG9999001176.USD","IE00BBT3K403.USD","LU1066051498.USD","BK4592","BK4588","GLP","IE00BLSP4452.SGD","SG9999002224.SGD","BK4534","SG9999003800.SGD","LU0306807586.USD","BK4599","LU0234572021.USD","LU0456855351.SGD","LU0321505868.SGD","SG9999011175.SGD","LU1883839398.USD","IE00BLSP4239.USD","LU0225284248.USD","SG9999001176.SGD","LU1894683348.USD","IE00B19Z3581.USD","BK4550"],"gpt_icon":1},{"id":"2514701922","title":"美股抗疫概念股漲跌不一，諾瓦瓦克斯醫藥跌逾7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514701922","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514701922?lang=zh_tw&edition=fundamental","pubTime":"2025-02-25 05:49","pubTimestamp":1740433797,"startTime":"0","endTime":"0","summary":"每经AI快讯，当地时间2月24日，美股抗疫概念股涨跌不一，Moderna跌超4%，吉利德科学涨近1%，诺瓦瓦克斯医药跌逾7%，BioNTech跌超2%，阿斯利康涨0.63%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202502253328109819.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202502253328109819.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4588","BK4568","BK4547","BK4585","BK4139","NVAX"],"gpt_icon":0},{"id":"2514770591","title":"BUZZ-Summit Therapeutics 因第四季度虧損擴大和投資者對交易的預期而下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2514770591","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514770591?lang=zh_tw&edition=fundamental","pubTime":"2025-02-25 03:23","pubTimestamp":1740425029,"startTime":"0","endTime":"0","summary":"2月24日 -  ** 药物开发商Summit Therapeutics SMMT.O股价下跌12.6%至19.33美元 ** 公司公布第四季度净亏损为6110万美元，分析师预计为亏损6054万美元。** 券商 Truist Securities 分析师表示：\"据我们从买方讨论中了解到的情况，他们对交易公告抱有一定的期望，或许比 SMMT 与辉瑞之间披露的交易更具经济性。** 券商补充说：\"我们认为，SMMT 参与投资者会议的变化可能不是潜在交易公告的良好指标\"。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nL3T3PF1CZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BBT3K403.USD","SG9999011175.SGD","BK4534","SMMT","LU0225771236.USD","LU0289739699.SGD","BK4592","BK4139","LU0306807586.USD","LU0306806265.USD","BK4599","LU0456855351.SGD","LU1066053197.SGD","BK4007","LU0234572021.USD","SG9999001176.USD","BK4588","SG9999002232.USD","LU1883839398.USD","SG9999001176.SGD","LU0170899867.USD","LU1894683348.USD","LU0122379950.USD","SG9999003800.SGD","LU0321505439.SGD","LU1057294990.SGD","IE00B19Z3B42.SGD","LU2488822045.USD","BK4550","BK4585","BK4568","IE00BLSP4239.USD","IE00B19Z3581.USD","LU0321505868.SGD","SG9999002224.SGD","LU0058720904.USD","IE00BLSP4452.SGD","LU0868494617.USD","SGXZ57979304.SGD","LU1023059063.AUD","LU1066051498.USD","LU0985481810.HKD","SG9999013999.USD","LU0225284248.USD","LU1894683264.USD","BK4533","BK4581","IE000M9KFDE8.USD","IE0002270589.USD"],"gpt_icon":1}],"pageSize":16,"totalPage":10,"pageCount":8,"totalSize":146}]}}